Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
China Pharmaceutical University
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 8, 2024
Discovery & Translation
Distillery spotlight: new ubiquitin-modulating mechanisms from academia
Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature
BioCentury | Feb 21, 2024
Distillery Therapeutics
Bivalent KEAP1 inhibitor for acute inflammatory diseases
BioCentury | Aug 2, 2023
Discovery & Translation
TRIM11 for tauopathies; plus TCRs that recognize multiple antigens and more
BioCentury’s roundup of translational innovations
BioCentury | Dec 31, 2020
Distillery Therapeutics
Combining cholesterol metabolism inhibition with T cell therapy for glioblastoma, melanoma
DISEASE CATEGORY: Cancer
INDICATION: Brain cancer; melanoma Tethering T cell therapies to an inhibitor of the cholesterol metabolism enzyme SOAT could enhance the cell therapy’s efficacy
INDICATION: Brain cancer; melanoma Tethering T cell therapies to an inhibitor of the cholesterol metabolism enzyme SOAT could enhance the cell therapy’s efficacy
BioCentury | Apr 3, 2020
Distillery Therapeutics
NUDT1 inhibitor-carrying nanoparticles for solid tumors
BioCentury | Feb 24, 2020
Distillery Therapeutics
Boosting ZEB1 levels could treat osteoporosis by promoting angiogenesis
Items per page:
1 - 10 of 29